442 related articles for article (PubMed ID: 22623685)
1. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
3. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
4. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
5. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
8. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.
Plaschke K; Kopitz J; Siegelin M; Schliebs R; Salkovic-Petrisic M; Riederer P; Hoyer S
J Alzheimers Dis; 2010; 19(2):691-704. PubMed ID: 20110613
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary tangles and tau phosphorylation.
Brion JP; Anderton BH; Authelet M; Dayanandan R; Leroy K; Lovestone S; Octave JN; Pradier L; Touchet N; Tremp G
Biochem Soc Symp; 2001; (67):81-8. PubMed ID: 11447842
[TBL] [Abstract][Full Text] [Related]
10. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
11. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
12. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients.
Kihira T; Suzuki A; Kondo T; Wakayama I; Yoshida S; Hasegawa K; Garruto RM
Neuropathology; 2009 Oct; 29(5):548-58. PubMed ID: 19323791
[TBL] [Abstract][Full Text] [Related]
14. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
[TBL] [Abstract][Full Text] [Related]
16. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
[TBL] [Abstract][Full Text] [Related]
17. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase.
Provias J; Jeynes B
Curr Neurovasc Res; 2008 Aug; 5(3):199-205. PubMed ID: 18691078
[TBL] [Abstract][Full Text] [Related]
18. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
19. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Cai Z; Zhao Y; Zhao B
Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
[TBL] [Abstract][Full Text] [Related]
20. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
